CD274 and esophageal squamous cell carcinoma: Recently, immunotherapy with immune check point-blocking antibodies targeting programmed death 1 or programmed death ligand 1 (PD-1 or PD-L1) has improved the outcomes of EC patients, especially ESCC (4, 5).